4.6 Editorial Material

Fluvastatin helps interferon-based therapy in chronic hepatitis C: Fact or fiction?

Journal

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 28, Issue 1, Pages 7-9

Publisher

WILEY
DOI: 10.1111/jgh.12024

Keywords

-

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Low Hepatitis B Core-Related Antigen Levels Correlate Higher Spontaneous Seroclearance of Hepatitis B Surface Antigen in Chronic Hepatitis B Patients With High Hepatitis B Surface Antigen Levels

Tai-Chung Tseng, Chieh Chiang, Chun-Jen Liu, Chun-Ming Hong, Tung-Hung Su, Hung-Chih Yang, Wan-Ting Yang, Chen-Hua Liu, Pei-Jer Chen, Jia-Horng Kao

Summary: This study aimed to explore the association between spontaneous seroclearance of hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen (HBcrAg) levels. The results showed that lower HBcrAg levels were associated with an increased likelihood of HBsAg seroclearance. Especially for patients with HBsAg levels >1000 IU/mL, HBcrAg levels <10,000 U/mL served as an independent predictor for HBsAg seroclearance.

GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications

Yu-Ming Cheng, Chia-Chi Wang, Jia-Horng Kao

Summary: A new nomenclature for metabolic associated fatty liver disease (MAFLD) was proposed in 2020, but its coherence with clinical demand remains controversial.

HEPATOLOGY INTERNATIONAL (2023)

Article Gastroenterology & Hepatology

Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan

Chen-Hua Liu, Cheng-Yuan Peng, Chun-Jen Liu, Chi-Yi Chen, Ching-Chu Lo, Kuo-Chih Tseng, Pei-Yuan Su, Wei-Yu Kao, Ming-Chang Tsai, Hung-Da Tung, Hao-Tsai Cheng, Fu-Jen Lee, Chia-Sheng Huang, Ke-Jhang Huang, Yu-Lueng Shih, Sheng-Shun Yang, Jo-Hsuan Wu, Hsueh-Chou Lai, Yu-Jen Fang, Po-Yueh Chen, Jow-Jyh Hwang, Chi-Wei Tseng, Wei-Wen Su, Chun-Chao Chang, Pei-Lun Lee, Jyh-Jou Chen, Chi-Yang Chang, Tsai-Yuan Hsieh, Chung-Hsin Chang, Yi-Jie Huang, Jia-Horng Kao

Summary: This multicenter study evaluated the efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for retreating East Asian patients with hepatitis C virus (HCV) infection who previously received NS5A direct-acting antivirals (DAAs). The results showed that SOF/VEL/VOX is highly effective and well-tolerated for these patients.

HEPATOLOGY INTERNATIONAL (2023)

Editorial Material Medicine, General & Internal

Highlights

Jia-Horng Kao

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2023)

Letter Gastroenterology & Hepatology

Remote and Short-Term Prediction of Spontaneous Hepatitis B Surface Antigen Seroclearance Reply

Tai-Chung Tseng, Jia-Horng Kao

GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naive patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry

Te-Sheng Chang, Chung-Feng Huang, Hsing-Tao Kuo, Ching-Chu Lo, Chien-Wei Huang, Lee-Won Chong, Pin-Nan Cheng, Ming-Lun Yeh, Cheng-Yuan Peng, Chien-Yu Cheng, Jee-Fu Huang, Ming-Jong Bair, Chih-Lang Lin, Chi-Chieh Yang, Szu-Jen Wang, Tsai-Yuan Hsieh, Tzong-Hsi Lee, Pei-Lun Lee, Wen-Chih Wu, Chih-Lin Lin, Wei-Wen Su, Sheng-Shun Yang, Chia-Chi Wang, Jui-Ting Hu, Lein-Ray Mo, Chun-Ting Chen, Yi-Hsiang Huang, Chun-Chao Chang, Chia-Sheng Huang, Guei-Ying Chen, Chien-Neng Kao, Chi-Ming Tai, Chun-Jen Liu, Mei-Hsuan Lee, Pei-Chien Tsai, Chia-Yen Dai, Jia-Horng Kao, Han-Chieh Lin, Wang-Long Chuang, Chi-Yi Chen, Kuo-Chih Tseng, Chao-Hung Hung, Ming-Lung Yu

Summary: The study analyzed the data of Taiwanese patients with chronic hepatitis C infection receiving 8-week glecaprevir/pibrentasvir therapy. The results showed good treatment efficacy with minimal adverse events. This is of great significance for the treatment of patients with compensated cirrhosis.

HEPATOLOGY INTERNATIONAL (2023)

Article Gastroenterology & Hepatology

Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B

Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Chi-Ling Chen, Shih-Jer Hsu, Sih-Han Liao, Chun-Ming Hong, Chen-Hua Liu, Ting-Yuan Lan, Hung-Chih Yang, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao

Summary: This study aimed to explore the impact of concurrent MAFLD on the risk of HCC in CHB patients. The study found that concurrent MAFLD reduced the risk of HCC in CHB patients, while an increasing burden of metabolic dysfunction increased the risk of HCC.

HEPATOLOGY INTERNATIONAL (2023)

Article Gastroenterology & Hepatology

Serial increase and high alpha-fetoprotein levels predict the development of hepatocellular carcinoma in 6 months

Tung-Hung Su, Shan-Han Chang, Chi-Ling Chen, Sih-Han Liao, Tai-Chung Tseng, Shih-Jer Hsu, Chun-Ming Hong, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao

Summary: The aim of this study was to evaluate the controversial use of AFP checkup with abdominal ultrasonography for HCC surveillance. It was found that serial AFP-increase and high AFP levels can predict the occurrence of HCC. AFP levels at 12, 9, and 6 months before the outcome date were evaluated. Group-based trajectory analysis and multivariable regression analysis were performed to identify AFP trajectories as risk predictors for HCC.

HEPATOLOGY RESEARCH (2023)

Article Gastroenterology & Hepatology

Diversity and composition of gut microbiota in healthy individuals and patients at different stages of hepatitis B virus-related liver disease

Meng-Ju Lin, Tung-Hung Su, Chieh-Chang Chen, Wei-Kai Wu, Shih-Jer Hsu, Tai-Chung Tseng, Sih-Han Liao, Chun-Ming Hong, Hung-Chih Yang, Chun-Jen Liu, Ming-Shiang Wu, Jia-Horng Kao

Summary: This study investigated the gut microbiota of patients with HBV-related liver diseases and found that the diversity and composition of the gut microbiota varies significantly between healthy individuals and patients at different stages of HBV-related liver disease. The study also revealed changes in microbial functions with disease progression, suggesting that understanding the gut microbiota may provide novel therapeutic options for these patients.

GUT PATHOGENS (2023)

Correction Gastroenterology & Hepatology

Diversity and composition of gut microbiota in healthy individuals and patients at different stages of hepatitis B virus-related liver disease (vol 15, 24, 2023)

Meng-Ju Lin, Tung-Hung Su, Chieh-Chang Chen, Wei-Kai Wu, Shih-Jer Hsu, Tai-Chung Tseng, Sih-Han Liao, Chun-Ming Hong, Hung-Chih Yang, Chun-Jen Liu, Ming-Shiang Wu, Jia-Horng Kao

GUT PATHOGENS (2023)

Article Gastroenterology & Hepatology

The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease

Pei-Shan Tsai, Yu-Ming Cheng, Chia-Chi Wang, Jia-Horng Kao

Summary: This study aimed to investigate the clinical outcomes of metabolic-associated fatty liver disease (MAFLD) patients with concomitant chronic hepatitis C virus (HCV) infection. The results showed that MAFLD patients with HCV infection may have a higher risk of advanced liver fibrosis, but a similar risk of atherosclerotic cardiovascular disease compared to those without HCV infection.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Serum RNase L levels in patients with chronic hepatitis B virus infection

Chi-Ling Chen, Tai-Chung Tseng, Chun-Jen Liu, Jia-Horng Kao, Pei-Jer Chen, Wei-Shiung Yang

Summary: This study reveals a positive relationship between serum RNase L levels and HBV viral titers or advanced disease status. Further investigation in this area may provide more details of an innate immune response for HBV and opportunity for novel therapeutic strategy.

HEPATOLOGY RESEARCH (2023)

Letter Medicine, General & Internal

New Approaches to Chronic Hepatitis B

Tai-Chung Tseng, Jia-Horng Kao

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Article Oncology

High PIVKA-II level and ASAP score predict 1-year risk of hepatocellular carcinoma in non-cirrhotic chronic hepatitis B patients

Yi-Cheng Lu, Tung-Hung Su, Tai-Chung Tseng, Shih-Jer Hsu, Sih-Han Liao, Chun-Ming Hong, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao

Summary: Protein induced by Vitamin K absence or antagonists-II (PIVKA-II) serves as a diagnostic marker for hepatocellular carcinoma (HCC). In this study, we investigated the predictive role of PIVKA-II and ASAP score in the development of HCC within 1 year among untreated chronic hepatitis B (CHB) patients. The results showed that baseline PIVKA-II level was significantly higher in the HCC group compared to the control group and could predict HCC development within 1 year. Furthermore, the ASAP score, which combines age, sex, alpha-fetoprotein, and PIVKA-II, improved the predictability for HCC within 1 year. The findings suggest that both high PIVKA-II level and ASAP score may serve as predictors for HCC development in untreated CHB patients, particularly in those with normal alpha-fetoprotein levels.

AMERICAN JOURNAL OF CANCER RESEARCH (2023)

No Data Available